A rapid and reliable method for the quantitation of hydroxychloroquine in serum using turbulent flow liquid chromatography-tandem mass spectrometry

Clinica Chimica Acta

Volumn 421, Issue , 2013, Pages 79-84

  Füzéry, Anna K ^a   Breaud, Autumn R ^a   Emezienna, Nkechinyere ^a   Schools, Sabitha ^a   Clarke, William A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Hydroxychloroquine; Mass spectrometry; Serum; Turbulent flow liquid chromatography

Indexed keywords

HYDROXYCHLOROQUINE SULFATE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; INTERMETHOD COMPARISON; LINEAR SYSTEM; PRECIPITATION; PRIORITY JOURNAL; RELIABILITY; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; TURBULENT FLOW LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

CHEMICAL PRECIPITATION; CHROMATOGRAPHY, LIQUID; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PERCHLORATES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84875653426     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.02.018     Document Type: Article

References (22)

1. Ben-Zvi I., Kivity S., Langevitz P., Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergol Immunol 2012, 42:145-153.
2. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011, 13:77-80.
3. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54:3284-3290.
4. Costedoat-Chalumeau N., Amoura Z., Hulot J.S., et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007, 66:821-824.
5. Munster T., Gibbs J.P., Shen D., et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002, 46:1460-1469.
6. Tett S.E., Cutler D.J., Beck C., Day R.O. Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis: a prospective, dose ranging study. J Rheumatol 2000, 27:1656-1660.
7. Francès C., Cosnes A., Duhaut P., et al. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus. Arch Dermatol 2012, 148:479-484.
8. Miller D.R., Fiechtner J.J., Carpenter J.R., Brown R.R., Stroshane R.M., Stecher V.J. Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. Arthritis Rheum 1987, 30:567-571.
9. Laaksonen A.L., Koskiahde V., Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 1974, 3:103-108.
10. Tett S.E., Cutler D.J., Day R.O., Brown K.F. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988, 26:303-313.
11. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at pictogram per milliliter concentrations. Anal Chem 1998, 70:882-889.
12. Viswanathan C.T., Bansal S., Booth B., et al. Workshop/Conference Report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J 2007, 9:E30-E42.
13. Tett S.E., Cutler D.J., Brown K.F. High-performance liquid chromatographic assay for hydroxychloroquine and metabolites in blood and plasma, using a stationary phase of poly(styrene divinylbenzene) and a mobile phase at pH 11, with fluorometric detection. J Chromatogr 1985, 344:241-248.
14. Brown R.R., Stroshane R.M., Benzinger D.P. High-performance liquid chromatographic assay for hydroxychloroquine and three of its major metabolites, desethylhydroxychloroquine, desethylchloroquine and bidesethylchloroquine, in human plasma. J Chromatogr 1986, 377:454-459.
15. Iredale J., Wainer I.W. Determination of hydroxychloroquine and its major metabolites in plasma using sequential achiral-chiral high-performance liquid chromatography. J Chromatogr 1992, 573:253-258.
16. Croes K., McCarthy P.T., Flanagan R.J. Simple and rapid HPLC of quinine, hydroxychloroquine, chloroquine, and desethylchloroquine in serum, whole blood, and filter paper-adsorbed dry blood. J Anal Toxicol 1994, 18:255-260.
17. McChesney E.W., Wyzan H.S., McAuliff J.P. The determination of 4-aminoquinoline antimalarials: revaluation of the induced fluorescence method, with specific application to hydroxychloroquine analysis. J Am Pharm Assoc 1956, 45:640-645.
18. Nation R.L., Hackett L.P., Dusci L.J., Ilett K.F. Excretion of hydroxychloroquine in human milk. Br J Clin Pharmacol 1984, 17:368-369.
19. McLachlan A.J., Tett S.E., Cutler D.J. High-performance liquid chromatographic separation of the enantiomers of hydroxychloroquine and its major metabolites in biological fluids using an [U+F061]1-acid glycoprotein stationary phase. J Chromatogr 1991, 570:119-127.
20. Fieger H., Iredale J., Wainer I.W. Enantioselective determination of hydroxychloroquine and its major metabolites in urine and the observation of a reversal in the (+)/(-)-hydroxychloroquine ratio. Chirality 1993, 5:65-70.
21. Wang L.Z., Ong R.Y.L., Chin T.M., et al. Method development and validation for rapid quantification of hydroxychloroquine in human blood using liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2012, 51:86-92.
22. Tett S.E., Cutler D.J., Day R.O., Brown K.F. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989, 27:771-779.